Eli Lilly

Johnson & Johnson

AbbVie

McKesson

Bristol-Myers

CoreSite Realty

Merck

Zoetis

Pfizer

Viatris

VanEck Vectors Pharmaceutical ETF

PPH tracks a market-cap-weighted index of 25 of the largest global pharmaceutical firms.

First Trust Nasdaq Pharmaceuticals ETF 

iShares U.S. Pharmaceuticals ETF

Invesco Dynamic Pharmaceuticals ETF

SPDR S&P Pharmaceuticals ETF

Many industry bigwigs reported solid results, with some beating on earnings or revenues or both.

Pharma ETFs in Focus Post Q3 Earnings

VanEck Pharmaceutical ETF has had the strongest one-year performance of four major pharmaceutical ETF competitors due to its unique mix of Novo Nordisk, Eli Lilly, and Johnson & Johnson. Eli Lilly, PPH's top holding, saw a 28% increase in Q2 revenue from its Mounjaro injection, a treatment for Type 2 diabetes. Recent medical treatments such as Ozempic and Wegovy are expected to drive $3.3 billion and $1.1 billion, respectively in revenue for Novo Nordisk in Q3 2023, PPH's second-largest holding.

PPH: A 'Shot In The Arm' For Investors Looking To Capitalize On Recent Pharmaceutical Advances

Eli Lilly is a mega-cap stock in the Health Care sector that has performed well in 2023, and it's the top holding in the VanEck Pharmaceutical ETF. I have a buy rating on the low-cost and style & geographically-diverse ETF. PPH offers a higher income compared to owning an S&P 500 index fund, but it carries technical risks and, but is top-heavy.

PPH: GLP-1 Companies And Large-Cap Value Pharma Make For A Compelling Portfolio

Global X Longevity Thematic ETF 

Global X Health & Wellness Thematic ETF

iShares MSCI Denmark ETF

First Trust Nasdaq Food & Beverage ETF 

iShares U.S. Medical Devices ETF

Invesco Dynamic Food & Beverage ETF

According to the latest CDC National Diabetes Statistics Report, more than 37 million people have diabetes in the U.S., or 11.3% of the population. The statistics for obesity are also dismal, as the World Health Organization reports the global obesity count at more than 1 billion.

Disruptive Tech Theme of the Week: Weight Loss Revolution

Ozempic commercials are, at this point, ubiquitous and while that's an anecdotal example, it also represents confirmation that obesity drugs are the next big thing in the pharmaceuticals industry.

Weight Loss Drugs Could Prove Potent for PPH

Breakwave Dry Bulk Shipping ETF

iPath Global Carbon ETN

United States Natural Gas Fund LP

Sprott Junior Uranium Miners ETF

Wall Street delivered a mixed performance last week.

6 Best-Performing ETFs of Last Week

Second-quarter earnings beat ratio of 86.6% and revenue beat ratio of 84.9% for the healthcare sector are impressive.

Pharma ETFs in Focus Post Q2 Earnings

iShares US Infrastructure ETF

Global X U.S. Infrastructure Development ETF

SPDR S&P Health Care Services ETF

Value-focused investing comes to rescue if high-growth sectors fail for some reasons.

Cautious on Big Tech & AI? Try These Value-Focused Sector ETFs

Pharmaceutical ETFs like PPH may introduce another layer of risk that could be avoided if one took a broader approach to healthcare investing. Technical Analysis displays that beneath the most recent uptrend, PPH is largely struggling to gain the same momentum seen back in March and is likely to remain range bound. Artificial Intelligence could enhance both the precision and speed of drug development and personalization, making PPH's long-term forecast potentially lucrative.

PPH: Unnecessary Volatility In A Relatively Stable Healthcare Sector (Technical Analysis)

DiCE Molecules Holding LLC

iShares U.S. Healthcare ETF

Harbor Health Care ETF

Horizon Kinetics Medical ETF

Health Care Select Sector SPDR Fund

Eli Lilly (LLY) has agreed to acquire DICE Therapeutics (DICE) in a cash deal worth approximately $2.4 billion. This strategic move is part of Eli Lilly's efforts to bolster its immunology pipeline, specifically targeting immune disease-related treatments.

ETFs to Capitalize on Eli Lilly's Buyout of DICE Therapeutics

AstraZeneca

Microsoft

Novartis

Industry-leading pharmaceutical firms are adopting artificial intelligence to drive value for the future of their enterprise. Several companies in the VanEck Pharmaceutical ETF are currently integrating AI into their operations.

How The Pharmaceutical Industry Is Using AI

Industry-leading pharmaceutical firms are adopting artificial intelligence (AI) to drive value for the future of their enterprise. AI is currently being implemented within the industry to reduce human error, streamline processes and analyze data to develop new pharmaceuticals.

How the Pharmaceutical Industry Is Using AI

Many industry bigwigs reported solid results, with some beating on earnings or revenues or both. As such, pharma ETFs have been in the green over the past month.

Pharma ETFs Gain Post Q1 Earnings

Vanguard Health Care ETF

Johnson & Johnson (JNJ) continued with its long streak of earnings beat. It topped the revenue estimate as well as lifted the full-year outlook.

ETFs to Buy on Solid Q1 JNJ Earnings Results

The US market is highly speculative right now, as it's bid up to levels comparable to before stresses in the banking system had been revealed by SVB Financial. PPH, which follows a broad basket of the pharmaceutical industry, fell as much as the general market.

PPH Fell As Much As The Market Despite Resilience

Virtus LifeSci Biotech Clinical Trials ETF

VanEck Vectors Biotech ETF

First Trust NYSE Arca Biotechnology Index Fund

iShares Nasdaq Biotechnology ETF

iShares U.S. Healthcare Providers ETF

Invesco Dynamic Biotechnology & Genome ETF

Invesco S&P 500 Equal Weight Health Care ETF

SPDR S&P Biotech ETF

How SVB's collapse is impacting healthcare startups. Pfizer to buy Seagen for $43B.

The Fall Of SVB: What It Means For Healthcare Startups

DaVita

Moderna

Active investors can navigate the boom or bust biotech sector with the help of strategies like C-suite buying, cash to value and cash flow. Passive investors seeking a defensive position might just purchase the VanEck Pharmaceutical ETF and call it a year.

Betting On Biotech

Combining the actual results with the estimates for the still-to-report companies, total earnings for the healthcare sector are expected to decline 9% on revenue growth of 4.3%.

A Look at Pharma ETFs Post Q4 Earnings

The world's biggest healthcare products' maker continued with its long streak of earnings beat and missed revenue estimates.

ETFs in Focus on JNJ's Mixed Q4 Earnings Results

We think that the bear market is coming to an end, as it must. The way to go is to invest in higher beta, or at least in more beaten down issues.

PPH Might Be Too Safe For A Recovering Market

ARK Genomic Revolution Multi-Sector ETF

Virtus LifeSci Biotech Products ETF

BlackRock Future Health ETF

Principal Healthcare Innovators Index ETF

Loncar Cancer Immunotherapy ETF

Global X Telemedicine & Digital Health ETF

Fidelity MSCI Health Care ETF

First Trust Health Care AlphaDEX Fund

Amplify Treatments Testing & Advancements ETF

Global X Genomics & Biotechnology ETF

 Franklin Genomic Advancements ETF

ROBO Global Healthcare Technology and Innovation ETF

Invesco Nasdaq Biotechnology ETF

iShares Genomics Immunology and Healthcare ETF

iShares Global Healthcare ETF

Global X Longevity Thematic ETF

First Trust Indxx Medical Devices ETF

Novo Nordisk

Direxion Daily Pharmaceutical & Medical Bull 3X Shares

Simplify Health Care ETF

Invesco S&P SmallCap Health Care ETF

Invesco DWA Healthcare Momentum ETF

ALPS Medical Breakthroughs ETF

Wisdomtree BioRevolution Fund

SPDR S&P Health Care Equipment ETF

How a recession could impact health care stocks in 2023. As Covid continues, what it could mean for the health care sector.

Can Health Care Stocks Outperform Again In 2023?

WisdomTree U.S. High Dividend Fund

iShares MSCI Chile ETF

iShares MSCI Brazil ETF

iShares Core High Dividend ETF

FlexShares High Yield Value-Scored Bond Index Fund

iShares U.S. Oil Equipment & Services ETF

Pacer Trendpilot US Large Cap ETF

Invesco S&P Ultra Dividend Revenue ETF

iShares MSCI Global Gold Miners ETF

Sprott Gold Miners ETF

SPDR Portfolio S&P 500 High Dividend ETF

Simplify Volatility Premium ETF

iShares MSCI Turkey ETF

SPDR S&P Oil & Gas Equipment & Services ETF

Stocks closed off a tumultuous year on a sour note in December. What's next for best ETFs?

Best ETFs Try To Emerge For A Better 2023 For Investors

Global X Education ETF

Global X Gold Explorers ETF

Global X Social Media ETF

iShares Virtual Work and Life Multisector ETF

December has been a brutal month for the U.S. stock market. The S&P 500 Index and the Dow Jones Industrial Index are down 5.8% and 4%, respectively, so far in December, while the tech-heavy Nasdaq Composite Index has lost 8.5%.

5 Sector ETFs That Beat the Market in December

For much of 2020 and 2021, the pharmaceutical stock investment thesis revolved around development and disbursement of coronavirus vaccines. While that made for an obvious catalyst, and a rewarding one at that, the effects of the COVID-19 vaccine status as an accelerant for pharma equities waned this year.

Growth, Innovation Could Fuel Pharma ETF Rebound

Amgen

Horizon Pharma

Amgen (AMGN) has agreed to buy Horizon Therapeutics PLC (HZNP) for $27.8 billion. This put the spotlight on pharma ETFs, which could be the best way for investors to tap the opportunity arising from the proposed deal.

Amgen to Buy Horizon Therapeutics: ETFs to Bet On

News for VanEck Vectors Pharmaceutical ETF ETF (PPH)